The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia
Top Cited Papers
- 10 May 2020
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 95 (9), 1006-1014
- https://doi.org/10.1002/ajh.25859
Abstract
For patients with high risk myeloid disease, allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy. Unfortunately, many of these patients relapse after HCT and have a limited survival. The recent approval of venetoclax, an orally bioavailable BCL‐2 inhibitor, resulted in significant responses in treatment naïve acute myeloid leukemia (AML) and off‐label use in the relapsed/refractory setting is increasing. We report the outcomes of 21 patients who underwent allogeneic HCT for myeloid disease, relapsed with AML, and were treated with venetoclax. Several patients had poor risk features including antecedent hematologic malignancy (6/21), complex karyotype (6/21), and TP53 mutations (5/21). The median age was 64.5 years and time from HCT to relapse was 5.7 months (range: 0.9 to 44.9 months). Of the 19 patients who were assessed for response, there were meaningful treatment responses seen in 8 patients: 5 CR, 3 CRi, 0 PR, for an ORR of 42.1%. Treatment effect was seen in 6 additional patients, including 4 morphologic leukemia free state. Nine patients maintained their response for ≥3 months and eight were receiving therapy at data cut. Post‐HCT AML relapse has an exceedingly poor outcome, and venetoclax‐based therapy is a potent therapy option that should be studied prospectively in this setting.This publication has 44 references indexed in Scilit:
- Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision AnalysisJournal of Clinical Oncology, 2013
- Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM groupLeukemia Research, 2012
- Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotypeBlood, 2012
- Acute Myeloid Leukemia With IDH1 or IDH2 MutationAmerican Journal of Clinical Pathology, 2011
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsBlood, 2010
- IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2010
- Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex KaryotypeJournal of Clinical Oncology, 2008
- A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcomeBlood, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002